Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iSpecimen (ISPC) Research & Development (2020 - 2025)

iSpecimen (ISPC) has 6 years of Research & Development data on record, last reported at $551104.0 in Q3 2025.

  • For Q3 2025, Research & Development fell 26.98% year-over-year to $551104.0; the TTM value through Sep 2025 reached $2.6 million, down 27.13%, while the annual FY2024 figure was $3.5 million, 1.03% down from the prior year.
  • Research & Development reached $551104.0 in Q3 2025 per ISPC's latest filing, up from $536311.0 in the prior quarter.
  • Across five years, Research & Development topped out at $967831.0 in Q4 2023 and bottomed at $361799.0 in Q2 2021.
  • Average Research & Development over 5 years is $696008.3, with a median of $740410.0 recorded in 2022.
  • Peak YoY movement for Research & Development: surged 75.69% in 2022, then plummeted 41.19% in 2025.
  • A 5-year view of Research & Development shows it stood at $522551.0 in 2021, then surged by 41.69% to $740410.0 in 2022, then soared by 30.72% to $967831.0 in 2023, then fell by 1.67% to $951667.0 in 2024, then crashed by 42.09% to $551104.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $551104.0 in Q3 2025, $536311.0 in Q2 2025, and $545367.0 in Q1 2025.